Product Overview
Composition
pharmachologic effect
Thus, the drug dissolves and prevents the formation of uric acid stones.
In addition, it enhances the excretion of citrates and reduces the excretion of calcium, improves the solubility of calcium oxalate in the urine, inhibits the formation of crystals and, therefore, prevents the formation of calcium-oxalate stones.
Bioavailability is about 100%. After taking Blemaren® for one day, the amount of sodium and potassium administered is excreted from the body by the kidneys for 24 to 48 hours.
With prolonged use of the drug, daily excretion of potassium and sodium corresponds to daily intake. In the blood or in the blood plasma, there are no significant changes in the indicators of gases in the blood or electrolytes.
This means that due to renal regulation of alkalization, the acid-base balance in the body is maintained, and the accumulation of sodium and potassium during normal renal function does not occur.
Indications
- dissolution of mixed uric acid-oxalate stones (with an oxalate content of less than 25%)
- alkalization of urine in persons receiving cytostatics or drugs that increase the excretion of uric acid; in the treatment of patients with cystine stones;
- symptomatic treatment of porphyria of the skin
Pregnancy and lactation
There is no confirmed data on the undesirable effect of the drug Blemaren® during pregnancy and during breastfeeding. Taking the drug is possible after consulting a doctor.
Contraindications
- Hypersensitivity;
- lactase deficiency, lactose intolerance, glucose-galactose malabsorption;
- acute and chronic renal failure;
- metabolic alkalosis;
- urinary tract infections caused by urea-splitting microorganisms;
- episodic hereditary adynamia;
- the need to follow a strict salt-free diet (for example, with severe forms of arterial hypertension);
- children's age up to 12 years (since there is no sufficient clinical experience regarding this age group).
Side effects
With individual intolerance to the components of the drug, allergic reactions are possible.
From the gastrointestinal tract: often - pain in the abdomen, nausea, vomiting, diarrhea.
From the side of metabolism and nutrition: the frequency is unknown - edema (sodium retention), metabolic alkalosis.
Interaction
The simultaneous administration of preparations containing citrates and aluminum can lead to increased absorption of aluminum. The interval between doses of such drugs should be at least 2 hours. The
effect of cardiac glycosides may be weakened when they are simultaneously prescribed with Blemaren®, due to the presence of potassium in the preparation.
Some drugs that lower blood pressure (aldosterone antagonists, potassium-sparing diuretics, angiotensin-converting enzyme blockers, sartans), as well as anti-inflammatory non-steroidal drugs and analgesics can reduce potassium excretion.
How to take, course of administration and dosage
The daily dose is evenly distributed in 3 equal parts and taken after meals throughout the day. Monitoring the effectiveness of the drug is carried out by determining the pH of fresh urine 3 times a day before the next dose with the help of indicator paper embedded in each pack.
The indicator zone of the test strip should be immersed in urine for 5-10 seconds, then removed and after 2 minutes compare the resulting color of the test strip with the color scale applied to the set of indicator strips. The resulting pH should be recorded in the control calendar, which is enclosed in a pack.
Based on the data obtained, the doctor selects an individual dosage for the purpose of effective therapy.
The dose is considered correctly selected if the pH during the day is within the recommended range for each indication.
To dissolve uric acid stones, urine pH should be between 7.0 - 7.2. In order to dissolve urea-oxalate mixed stones and prevent the formation of calcium-oxalate stones, urine pH must be maintained at 6.8 - 7.4.
For alkalization of urine in patients with cystine stones, the pH of the urine should be in the range of 7.5 - 8.5. For the treatment of porphyria, urine pH should be between 7.2 and 7.5. In the treatment of cytostatics, urine pH should be at least 7.0. If the pH value of urine is lower than indicated, the dose must be increased, if it is higher, then reduced. The duration of treatment is at least 4-6 months.
In the presence of cystine stones and the treatment of porphyria, a special indicator paper should be used to monitor the effectiveness in order to determine the pH in the range of 7.2 - 9.7 (not included).
Overdose
In normal renal function, an undesirable effect of the drug on changes in physiological parameters of metabolism was not observed either at the usual recommended dose or at a higher one, since the release of excess alkalis by the kidneys is a natural mechanism for regulating the acid-base balance in the body.
The upper limit of the urine pH range indicated above should not be exceeded for several days, since there is an increased risk of phosphate crystallization due to an increase in pH (pH> 7.8).
Possible overdose can be corrected by reducing the dose of the drug. If necessary, measures can be taken to treat metabolic alkalosis.
Description
Special instructions
The average daily dose (4 effervescent tablets) contains about 1.5 mg of potassium and 0.9 g of sodium (should be considered in patients with limited intake of salt).
It can be used in chronic renal failure, not accompanied by a delay in potassium ions.
It can be prescribed to patients with diabetes.
When dissolving uric acid stones, one should not allow excessive urine alkalization for many days, since with an increase in pH above 7.8 a precipitate of phosphate soda may appear on the surface of uric acid crystals, which may prevent their further dissolution.
During treatment, you should limit the intake of foods rich in proteins and purine bases, and also ensure sufficient fluid intake (at least 1.5-2 liters).
Release form
Effervescent tablets.
